沈阳色素性紫癜怎么治疗沈阳在线咨询痘痘问题,沈阳肤康皮肤病医院治皮肤科收费高不高,沈阳怎样治疗好荨麻疹,沈阳看过敏皮肤哪个医院较好,沈阳哪家医院荨麻疹肤康很hao,沈阳肤康皮肤病医院治疗皮肤科怎么样正规么,沈阳治疗皮肤过敏到哪家医院

BEIJING, Jan. 24 (Xinhua) -- China's meteorological authority said Tuesday that the country's northern regions will continue to have sunny weather for the coming 24 hours, while the south will see subdued rain and snow.Temperatures in most parts of the country are expected to rebound slightly, the National Meteorological Center said in a statement on its website.But the lowest temperatures in the areas south of the Yangtze River will remain around zero degree Celsius, the center said.Meanwhile, rain and snow will subdue in most parts of the southern regions over the next three days, although freezing rain is forecast to hit Guizhou and Hunan provinces, according to the statement.

WASHINGTON, Dec. 7 (Xinhua) -- The use of two drugs never tried in combination before in ovarian cancer resulted in a 70 percent destruction of cancer cells already resistant to commonly used chemotherapy agents, say researchers at Mayo Clinic in Florida.Their report, published on-line Wednesday in Gynecologic Oncology, suggests that this combination, ixabepilone and sunitinib, might offer a much needed treatment option for women with advanced ovarian cancer.Neither drug is approved for use in ovarian cancer. Ixabepilone is a chemotherapy drug that, like other taxane drugs, targets the microtubules and stops dividing cells from forming a spindle. It has been approved for use in metastatic breast cancer. Sunitinib, approved for use in kidney cancer, belongs to a class of tyrosine kinase inhibitors that stops growth signals from reaching inside cancer cells.When caught at late stages, ovarian cancer is often fatal because it progressively stops responding to the chemotherapy drugs used to treat it."Women die from ovarian cancer because their tumors become resistant to chemotherapy, so a drug that might be able to reduce that resistance -- which may be what this combination of agents is doing -- would be a boon to treatment of this difficult cancer," says study coauthor Gerardo Colon-Otero.The finding also highlights the importance of the role of a molecule, RhoB, that the researchers say is activated by the drug duo. It might be a potential biomarker that may help identify patients who might benefit from such combination therapy, the researchers say.

SAN FRANCISCO, Oct. 14 (Xinhua) -- Google on Friday announced to shut down the highly-controversial social networking product Google Buzz, along with several other services in the coming weeks.On the company's official blog, Google announced the death penalty to its code search engine, Buzz, Jaiku which let users send updates to friends, the Google personalized homepage feature iGoogle, and the University Research Program for Google Search.The shut-downs came as part of Google's housecleaning effort announced in early September, in which the company said it will shut down a number of products and merging others into existing products as features."Changing the world takes focus on the future, and honesty about the past. We learned a lot from products like Buzz, and are putting that learning to work every day in our vision for products like Google+. Our users expect great things from us; today's announcements let us focus even more on giving them something truly awesome," said Google in the blog post.Google Buzz, a social networking and messaging tool integrated into Gmail service, has been widely criticized for privacy concerns and held back the search giant from expanding its businesses to the social networking space.After Buzz, Google launched Google+ in June, which has been receiving a good response and passed the 40 million user mark, the company's chief executive officer Larry Page said Thursday.

SAN FRANCISCO, Nov. 9 (Xinhua) -- Cisco Systems Inc., the world 's biggest networking equipment maker, on Wednesday reported that its profit fell about 7.9 percent in the most recent quarter.In the company's fiscal 2012 first quarter ending on Oct. 29, Cisco posted its net income of nearly 1.78 billion U.S. dollars, compared with 1.93 billion dollars in the same period a year earlier.Excluding some items, earnings per share in the quarter were 43 cents, better than the 39 cents estimated by analysts, according to Bloomberg.Cisco's sales in the quarter reached 11.26 billion dollars, an increase of 4.7 percent year-on-year and also topped analysts' projection of about 11 billion dollars."We delivered a solid quarter," John Chambers, Cisco's chief executive officer, said in a statement."We've completed the majority of our restructuring and have organized Cisco to successfully execute against our strategy of providing intelligent networks, architectures and integrated products that solve customers' business problems," he added.